.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Healthtrust
Dow
Argus Health
Teva
McKesson
Baxter
Colorcon
Fuji

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,794,432

« Back to Dashboard

Which drugs does patent 7,794,432 protect, and when does it expire?


Patent 7,794,432 protects EPIPEN and EPIPEN JR. and is included in one NDA. There have been zero Paragraph IV challenges on Epipen and Epipen Jr.

This patent has thirty-three patent family members in seventeen countries.

Summary for Patent: 7,794,432

Title:Automatic injector with kickback attenuation
Abstract:An auto-injector for dispensing a predetermined dose of medicament is disclosed. The auto-injector includes a needle cover operative to engage an injection site. The needle cover is configured to move from a retracted position prior to a medicament dispensing operation to an extended locked position after the medicament dispensing operation. Any residual activation force remaining after the medicament dispensing operation is contained within the auto-injector and is not directed to the needle cover, thus attenuating, if not eliminating, any kickback effect.
Inventor(s): Young; Matthew Egerton (Over Cambs, GB), Raven; Sophie Rebecca (Swavesey Cambs, GB), Murphy; Martin Joseph (Letchworth Garden City Herts, GB), Hurlstone; Christopher John (Newport Saffron Walden Essex, GB), Daintrey; Joseph William (Royston Herts, GB), Rochford; Craig Malcolm (Monxton Andover Hants, GB), Kirkwood; Stephen Philip (Haynes Beds, GB), Mathews; Colin James (Godmanchester Huntingdon, GB), Hill; Robert L. (Abingdon, MD), Wilmot; John Glyndwr (Mount Airy, MD)
Assignee: Meridian Medical Technologies, Inc. (Columbia, MD)
Application Number:11/923,729
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mylan Speciality Lp
EPIPEN
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-001Dec 22, 1987BXRXYesYes► Subscribe► SubscribeY
Mylan Speciality Lp
EPIPEN JR.
epinephrine
INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS019430-002Dec 22, 1987BXRXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,794,432

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,449,012Automatic injector► Subscribe
9,586,010Automatic injector with needle cover► Subscribe
8,870,827Automatic injector► Subscribe
8,048,035Automatic injector with needle cover► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,794,432

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
TaiwanI407981► Subscribe
Taiwan200613027► Subscribe
SloveniaEP2311510► Subscribe
SloveniaEP2179759► Subscribe
SloveniaEP1786491► Subscribe
Singapore139748► Subscribe
Portugal2311510► Subscribe
Portugal2179759► Subscribe
Mexico2007001298► Subscribe
South Korea20070083539► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Citi
US Army
Medtronic
Chubb
Cerilliant
UBS
QuintilesIMS
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot